Repurposing of long-acting FDA-approved GLP-1 receptor agonists such as semaglutide, the dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist tirzepatide, and the triple-agonist retatrutide which additionally targets glucagon receptors and is currently in clinical trials for obesity, may offer a promising strategy treating AUD
Long-term follow-up data suggests that patients who maintain semaglutide therapy experience durable improvements in HbA1c levels, with some achieving complete normalization of blood glucose metrics
Sometimes it can be very discouraging to achieve weight loss, yet still have to contend with excess skin
Foam microbubbles can reach the heart, lungs and brain (during leg vein treatment) and may cause transient headaches, visual disturbances and coughing
It also slows down your stomachs emptying speed, increasing the length of time between urges to eat
& You, M